Skip to content

Pharminent

Primary Menu
  • Home
    • Pro Hub
Light/Dark Button
Hub
  • Home
  • Clinical Data
  • UCB reports positive outcomes for bimekizumab in psoriatic arthritis
  • Clinical Data

UCB reports positive outcomes for bimekizumab in psoriatic arthritis

PharmaTimes

Trial shows first headtohead superiority in joint endpoints for an approved PsA biologic

Immunology & Inflammation

Read full story

pharminent May 19, 2026 (Last updated: May 19, 2026)

PharmaTimes

Trial shows first headtohead superiority in joint endpoints for an approved PsA biologic

Immunology & Inflammation

Read full story

Post navigation

Previous: European study shows inequality in access to new medicines
Next: BioMarin suffers another blow to rare disease portfolio in Phase 3 flop

Related Stories

  • Clinical Data

Novartis hit as Lp(a) drug fails cardio outcomes trial

pharminent September 7, 2026
  • Clinical Data

Major trial of Roche Alzheimer’s drug kicks off in Europe

pharminent September 7, 2026
  • Clinical Data

AbbVie’s T cell engager delivers survival benefit in Phase 3 multiple myeloma study

pharminent September 4, 2026
  • Home
  • Contact
© 2026 All rights reserved. | ReviewNews by AF themes.